First-in-human phase I study of ELVN-001, an oral, selective BCR::ABL1 tyrosine kinase inhibitor, in patients with chronic myeloid leukemia who failed prior tyrosine kinase inhibitors Meeting Abstract
| Authors: | Mauro, M.; Lang, F. B.; Kim, D. W.; Heinrich, M.; Sasaki, K.; Lyssikatos, J.; Collins, H.; Hochhaus, A. |
| Abstract Title: | First-in-human phase I study of ELVN-001, an oral, selective BCR::ABL1 tyrosine kinase inhibitor, in patients with chronic myeloid leukemia who failed prior tyrosine kinase inhibitors |
| Meeting Title: | 11th Annual Meeting of the Society of Hematologic Oncology (SOHO 2023): Progress in Personalized Therapy |
| Keywords: | cml; chronic myeloid leukemia; tyrosine kinase inhibitor; phase i; bcr::abl1; elvn-001 |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 23 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Sep 6-9 |
| Meeting Location: | Houston, TX |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2023-09-01 |
| Start Page: | S345 |
| Language: | English |
| ACCESSION: | WOS:001062479600281 |
| PROVIDER: | wos |
| DOI: | 10.1016/S2152-2650(23)01148-5 |
| Notes: | Meeting Abstract: CML-487 -- Source: Wos |
